A systematic review of transition studies of pulmonary arterial hypertension specific medications

Avraham Sofer, Michael J. Ryan, Ryan J. Tedford, Joel A. Wirth, Wassim H. Fares

Research output: Contribution to journalReview article

Abstract

Pulmonary arterial hypertension (PAH) is a progressive potentially fatal disease. Multiple pharmacologic options are now available, which facilitated transitions between different therapeutic options, although the evidence for such transitions has not been well described. We sought to review the evidence supporting the safety and/or efficacy of transitioning between PAH-specific medications. We performed a systematic review of all published studies in the Medline database between 1 January 2000 and 30 June 2016 reporting on any transition between the currently Food and Drug Administration (FDA)-approved PAH-specific medications. Studies reporting on three or more adult patients published in the English language reporting on transitions between FDA approved PAH medications were extracted and tabulated. Forty-one studies met the selection criteria, nine of which included less than eight patients (and thus were reported separately in the supplement), for a total of 32 studies. Transitioning from parenteral epoprostenol to parenteral treprostinil appears to be safe and efficacious in patients who have less severe disease and more favorable hemodynamics. Transitioning from a prostacyclin analogue to an oral medication may be successful in patients who have favorable hemodynamics and stable disease. There is conflicting evidence supporting the transition from a parenteral to an inhaled prostacyclin analogue, even in patients who are on background oral therapy. Currently, the only evidence in support of transitioning between oral PDE5 inhibitors is from sildenafil to tadalafil. Patients on higher doses of sildenafil are more likely to fail. In patients with liver abnormalities due to bosentan or sitaxentan, the transition to ambrisentan appears to be safe and can result in clinical improvement. Studies regarding PAH medication transitions are limited. Patients who have less severe disease, better functional status, and are on lower medications doses may be more successful at transitioning.

LanguageEnglish (US)
Pages326-338
Number of pages13
JournalPulmonary Circulation
Volume7
Issue number2
DOIs
StatePublished - 2017

Fingerprint

Pulmonary Hypertension
Epoprostenol
United States Food and Drug Administration
Hemodynamics
Phosphodiesterase 5 Inhibitors
Patient Selection
Language
Databases
Safety
Liver
Therapeutics

Keywords

  • Pharmacotherapy
  • Pulmonary arterial hypertension
  • Pulmonary hypertension
  • Pulmonary vascular disease
  • Transition

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Sofer, A., Ryan, M. J., Tedford, R. J., Wirth, J. A., & Fares, W. H. (2017). A systematic review of transition studies of pulmonary arterial hypertension specific medications. Pulmonary Circulation, 7(2), 326-338. DOI: 10.1177/2045893217706357

A systematic review of transition studies of pulmonary arterial hypertension specific medications. / Sofer, Avraham; Ryan, Michael J.; Tedford, Ryan J.; Wirth, Joel A.; Fares, Wassim H.

In: Pulmonary Circulation, Vol. 7, No. 2, 2017, p. 326-338.

Research output: Contribution to journalReview article

Sofer, A, Ryan, MJ, Tedford, RJ, Wirth, JA & Fares, WH 2017, 'A systematic review of transition studies of pulmonary arterial hypertension specific medications' Pulmonary Circulation, vol 7, no. 2, pp. 326-338. DOI: 10.1177/2045893217706357
Sofer, Avraham ; Ryan, Michael J. ; Tedford, Ryan J. ; Wirth, Joel A. ; Fares, Wassim H./ A systematic review of transition studies of pulmonary arterial hypertension specific medications. In: Pulmonary Circulation. 2017 ; Vol. 7, No. 2. pp. 326-338
@article{fecaba93b4cc44f7a2283f5ddca70153,
title = "A systematic review of transition studies of pulmonary arterial hypertension specific medications",
abstract = "Pulmonary arterial hypertension (PAH) is a progressive potentially fatal disease. Multiple pharmacologic options are now available, which facilitated transitions between different therapeutic options, although the evidence for such transitions has not been well described. We sought to review the evidence supporting the safety and/or efficacy of transitioning between PAH-specific medications. We performed a systematic review of all published studies in the Medline database between 1 January 2000 and 30 June 2016 reporting on any transition between the currently Food and Drug Administration (FDA)-approved PAH-specific medications. Studies reporting on three or more adult patients published in the English language reporting on transitions between FDA approved PAH medications were extracted and tabulated. Forty-one studies met the selection criteria, nine of which included less than eight patients (and thus were reported separately in the supplement), for a total of 32 studies. Transitioning from parenteral epoprostenol to parenteral treprostinil appears to be safe and efficacious in patients who have less severe disease and more favorable hemodynamics. Transitioning from a prostacyclin analogue to an oral medication may be successful in patients who have favorable hemodynamics and stable disease. There is conflicting evidence supporting the transition from a parenteral to an inhaled prostacyclin analogue, even in patients who are on background oral therapy. Currently, the only evidence in support of transitioning between oral PDE5 inhibitors is from sildenafil to tadalafil. Patients on higher doses of sildenafil are more likely to fail. In patients with liver abnormalities due to bosentan or sitaxentan, the transition to ambrisentan appears to be safe and can result in clinical improvement. Studies regarding PAH medication transitions are limited. Patients who have less severe disease, better functional status, and are on lower medications doses may be more successful at transitioning.",
keywords = "Pharmacotherapy, Pulmonary arterial hypertension, Pulmonary hypertension, Pulmonary vascular disease, Transition",
author = "Avraham Sofer and Ryan, {Michael J.} and Tedford, {Ryan J.} and Wirth, {Joel A.} and Fares, {Wassim H.}",
year = "2017",
doi = "10.1177/2045893217706357",
language = "English (US)",
volume = "7",
pages = "326--338",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "2",

}

TY - JOUR

T1 - A systematic review of transition studies of pulmonary arterial hypertension specific medications

AU - Sofer,Avraham

AU - Ryan,Michael J.

AU - Tedford,Ryan J.

AU - Wirth,Joel A.

AU - Fares,Wassim H.

PY - 2017

Y1 - 2017

N2 - Pulmonary arterial hypertension (PAH) is a progressive potentially fatal disease. Multiple pharmacologic options are now available, which facilitated transitions between different therapeutic options, although the evidence for such transitions has not been well described. We sought to review the evidence supporting the safety and/or efficacy of transitioning between PAH-specific medications. We performed a systematic review of all published studies in the Medline database between 1 January 2000 and 30 June 2016 reporting on any transition between the currently Food and Drug Administration (FDA)-approved PAH-specific medications. Studies reporting on three or more adult patients published in the English language reporting on transitions between FDA approved PAH medications were extracted and tabulated. Forty-one studies met the selection criteria, nine of which included less than eight patients (and thus were reported separately in the supplement), for a total of 32 studies. Transitioning from parenteral epoprostenol to parenteral treprostinil appears to be safe and efficacious in patients who have less severe disease and more favorable hemodynamics. Transitioning from a prostacyclin analogue to an oral medication may be successful in patients who have favorable hemodynamics and stable disease. There is conflicting evidence supporting the transition from a parenteral to an inhaled prostacyclin analogue, even in patients who are on background oral therapy. Currently, the only evidence in support of transitioning between oral PDE5 inhibitors is from sildenafil to tadalafil. Patients on higher doses of sildenafil are more likely to fail. In patients with liver abnormalities due to bosentan or sitaxentan, the transition to ambrisentan appears to be safe and can result in clinical improvement. Studies regarding PAH medication transitions are limited. Patients who have less severe disease, better functional status, and are on lower medications doses may be more successful at transitioning.

AB - Pulmonary arterial hypertension (PAH) is a progressive potentially fatal disease. Multiple pharmacologic options are now available, which facilitated transitions between different therapeutic options, although the evidence for such transitions has not been well described. We sought to review the evidence supporting the safety and/or efficacy of transitioning between PAH-specific medications. We performed a systematic review of all published studies in the Medline database between 1 January 2000 and 30 June 2016 reporting on any transition between the currently Food and Drug Administration (FDA)-approved PAH-specific medications. Studies reporting on three or more adult patients published in the English language reporting on transitions between FDA approved PAH medications were extracted and tabulated. Forty-one studies met the selection criteria, nine of which included less than eight patients (and thus were reported separately in the supplement), for a total of 32 studies. Transitioning from parenteral epoprostenol to parenteral treprostinil appears to be safe and efficacious in patients who have less severe disease and more favorable hemodynamics. Transitioning from a prostacyclin analogue to an oral medication may be successful in patients who have favorable hemodynamics and stable disease. There is conflicting evidence supporting the transition from a parenteral to an inhaled prostacyclin analogue, even in patients who are on background oral therapy. Currently, the only evidence in support of transitioning between oral PDE5 inhibitors is from sildenafil to tadalafil. Patients on higher doses of sildenafil are more likely to fail. In patients with liver abnormalities due to bosentan or sitaxentan, the transition to ambrisentan appears to be safe and can result in clinical improvement. Studies regarding PAH medication transitions are limited. Patients who have less severe disease, better functional status, and are on lower medications doses may be more successful at transitioning.

KW - Pharmacotherapy

KW - Pulmonary arterial hypertension

KW - Pulmonary hypertension

KW - Pulmonary vascular disease

KW - Transition

UR - http://www.scopus.com/inward/record.url?scp=85021296780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021296780&partnerID=8YFLogxK

U2 - 10.1177/2045893217706357

DO - 10.1177/2045893217706357

M3 - Review article

VL - 7

SP - 326

EP - 338

JO - Pulmonary Circulation

T2 - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 2

ER -